The FDA has communicated to Stealth BioTherapeutics that it would not meet elamipretide’s PDUFA target date for the treatment of Barth syndrome.

For older adults in the Western United States, exposure to high levels of smoke pollution is associated with an increase in hospitalizations for respiratory diseases.

An estimated 7.2 million Americans aged 65 years and older are living with Alzheimer dementia, and almost all adults feel it is important to diagnose the disease in the early stages.

The Food and Drug Administration (FDA) has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older who are ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Maternal hypertensive disorders of pregnancy (HDP) are associated with adverse cognitive and language development in preterm infants at 2 years' corrected age.

Ultrasound-guided minimally invasive tenosynovial biopsy is a feasible, safe, and well-tolerated technique among patients with different stages of RA.

Despite widespread vaccine availability and improved treatment strategies, certain patients with SARDs remain highly vulnerable to severe COVID-19 outcomes.

Changes in PROs can predict disease flares among patients with RA who discontinued csDMARD therapy after achieving sustained remission.

Denosumab plus romosozumab vs denosumab only was associated with improved bone mineral density among patients with severe postmenopausal osteoporosis.

Combination rituximab and IVIG therapy may be a viable treatment option for patients with refractory autoimmune diseases, though the quality of evidence is low.

Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes.